Adjuvant Therapies Can Reduce Recurrence Risk, But Carry Own Issues


October 8, 2012

Given the persistent nature of cancer, drug treatment for some cancers often extends for years in the form of adjuvant therapies – even if cancerous cells can't be visibly detected after initial treatment ends. An article in the Chicago Tribune examines the use of these drugs, mentioning research led by Robert Vonderheide, MD, DPhil, associate director for Translational Research in the Abramson Cancer Center, which showed a one-time infusion of the drug Zenapax (daclizumab) improved the survival of breast cancer patients given several doses of cancer vaccines by 30 percent, compared to those patients not taking daclizumab. The article was also published in the the San Jose Mercury, the Sacramento Bee and other newspapers across the nation.

Read more at Chicago Tribune.